Atomwise is a technology-enabled pharmaceutical company leveraging the power of AI to revolutionize small molecule drug discovery. The Atomwise team invented the use of deep learning for structure-based drug design; this technology underpins Atomwise’s best-in-class AI discovery engine, which is differentiated by its ability to find and optimize novel chemical matter.
Atomwise has extensively validated its discovery engine, delivering success in over 185 projects to-date including a wide-variety of protein types and numerous “hard-to-drug” targets. Atomwise is building a wholly-owned pipeline of small-molecule drug candidates, with three programs in lead-optimization and over 30 programs in discovery.
The company has raised over $174 million from leading venture capital firms to advance its mission to make better medicines, faster.
Learn more at atomwise.com, or connect on Twitter and LinkedIn.
Abraham Heifets is the CEO of Atomwise, which uses artificial intelligence to help discover new medicine. Abraham was a Massey Fellow at the University of Toronto and the Ontario Brain Institute, where his doctoral work used machine learning to help plan organic syntheses, a long-standing challenge in chemistry. Previously, Abraham researched high-performance data processing at IBM's T.J. Watson Research Center and contributed to the artificial intelligence system of the world-champion robotic soccer team at Cornell University, from which he holds two previous degrees. Abraham has presented his work at the National Institutes of Health, the American Chemical Society, and the Association for the Advancement of Artificial Intelligence. He is an author on 19 papers, patents, and patent applications. Abraham was also named Time Magazine's Person of the Year in 2006.
